Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Safe Use Initiative Targets NSAIDs, Pediatric Dosing, Drug-Impaired Driving

This article was originally published in The Tan Sheet

Executive Summary

CDER touts its Safe Use Initiative as addressing OTC and Rx mis-use and reducing risks to consumers by partnering with industry stakeholders and health care professionals. CDER Professional Affairs and Stakeholder Engagement Director John Whyte says he wants to “build capacity” behind the program.

You may also be interested in...

Draft Guidance Drills Down With Details To Cut Pediatric Acetaminophen Overdose Risk

FDA suggests new and repeats previous recommendations to reduce the risk of pediatric overdose with acetaminophen products due either to unsupervised ingestion or therapeutic errors. The guidance includes greater detail on delivery devices and labeling information for pediatric acetaminophen OTCs.

CDER Outreach Coordinator’s First Task Is Safe Use Initiative

John Whyte joins FDA from Discovery Channel to be director of professional affairs and stakeholder engagement.

Estee Lauder Companies Signals Growing Luxury Appetite, Possible M&A On Horizon

ELC’s Guillaume Jesel has been named president of global brands overseeing Tom Ford Beauty and Balmain Beauty, the latter targeted for launch in fall 2024 under a licensing agreement with the French fashion house announced on 26 September. Jesel also will head up luxury business development with a “key role in prospective acquisitions and investment strategy.”


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts